TIF has proudly organised the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which took place online on 11 – 13 December 2020.
Organised in the context of TIF’s internationally renowned educational programme and the THALIA project’s activities, the Symposium aimed at patients and doctors specialising in the field of haemoglobin disorders, presenting an ideal opportunity for an exchange of knowledge on the latest scientific advances in the field, and for participants to share their concerns and views.
The objectives of the Symposium were to inform the medical and patient communities on the state-of-art clinical management of thalassaemia and sickle cell disease and to develop the skills and capacities of patients and patients associations. It also focused on the latest scientific developments in the field, on recent authorisations of new drugs and therapies, and on extending knowledge through sharing experiences.
With an agenda that covered the latest advances in research, recent regulatory authorisations of therapies for the care and cure of thalassaemia and sickle cell disease by the European Medicines Agency (EMA), as well as the multidisciplinary care required for appropriate clinical management through case presentations, the Symposium also dealt with topics of major interest concerning patients and their quality of life.
Special focus was placed on patients’ disease education and the empowerment of patients and their families, whose representation and participation is extremely important at all levels of decision-making bodies, nationally and regionally.